IN8bio Announces Positive Glioblastoma Multiforme (GBM) Clinical Updates from the INB-200 Phase 1 Trial Presented at ASCO 2022GlobeNewsWire • 06/06/22
IN8bio Announces Data Emerging from its Recently Unveiled Gamma-Delta T cell “Off-the-Shelf” Induced Pluripotent Stem Cell PlatformGlobeNewsWire • 05/17/22
IN8bio Reports First Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/12/22
IN8bio Unveils Induced Pluripotent Stem Cell (iPSC) Platform at ASGCT 25th Annual MeetingGlobeNewsWire • 05/05/22
IN8bio Continues to Build on its Clinical and Regulatory Team with Two Key AppointmentsGlobeNewsWire • 04/13/22
IN8bio Presents Clinical Update from the Ongoing Phase 1 Trial of INB-100, an Allogeneic Gamma-Delta T Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell TransplantGlobeNewsWire • 03/28/22
IN8bio Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/17/22
IN8bio to present at Bio CEO & Investor Conference and Next Generation CAR-TCR SummitGlobeNewsWire • 02/10/22
IN8bio Announces Clinical Updates from the Phase 1 Clinical Trial of its Genetically Modified Gamma-Delta T Cell Therapy in Newly Diagnosed Glioblastoma MultiformeGlobeNewsWire • 01/06/22
IN8bio Provides Update from the Ongoing Phase 1 Clinical Trial of its Allogeneic Gamma-Delta T Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell TransplantGlobeNewsWire • 12/16/21
IN8bio to Present Preclinical Data on the Potential for Gamma-Delta T-cell Therapy Combinations with PARP and Checkpoint Inhibitors in Solid TumorsGlobeNewsWire • 11/11/21
IN8bio Reports Third Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/10/21
IN8bio to Present at Scientific Conferences in November: PEGS Europe, SITC and SNOGlobeNewsWire • 11/04/21
IN8bio's Announces Peer-Reviewed Publication of Preclinical Results Using Proprietary MGMT-modified Gamma-Delta T Cells (INB-200) with Temozolomide in Mouse Models of Glioblastoma MultiformeGlobeNewsWire • 10/27/21
IN8bio to Present at BioFuture 2021 and Advanced Therapies Congress & Expo 2021GlobeNewsWire • 10/04/21
IN8bio Reports Second Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewsWire • 09/10/21
IN8bio to Present at the NewYorkBIO Virtual Breakfast Series and H.C. Wainwright 23rd Annual Global Investment ConferenceGlobeNewsWire • 08/30/21